Tech Review

From development to launch

20.08.2011

Developing a new drug that addresses an unmet medical need is a challenging but rewarding objective in the life of a drug-development scientist. But even after a candidate has been identified and regulatory hurdles successfully cleared, there are always a set of new challenges that loom on a new drug’s path to commercial scale manufacturing.

Because time-to-market, risk reduction and production costs heavily influence the overall success of new products, the best time to optimise these key factors of success are the very early planning and development stages of the process, while various options are still under consideration. Managing individual steps from drug development to large scale manufacture requires an approach that efficiently balances know-how between formulation science, pharmaceutical process development and drug delivery technologies, while at the same time meeting the highest standards of quality, safety and stability.
In an era of increasing globalisation and a constantly changing pharmaceutical value chain, top-notch efficiency in developing new drugs – coupled with profound expertise and highly reliable quality of outsourced services – are the biggest hurdles for competitive pharmaceutical companies facing a challenging market environment.
To meet client demand, ProJect Pharmaceutics has developed a unique process for constantly planning, controlling and auditing this highly complex service, thus making it as transparent as possible for areas like risk reduction, time-line definition and cost efficiency.

Advaceutics

Advaceutics – a combination of the terms advantage and pharmaceutics – is the trademarked approach developed by ProJect Pharmaceutics that ensures seamless and integrated process management during all of the required steps that transform proteins, peptides and delicate small molecules into a manufacturable drug. Optimised and tailor-made solutions developed under the Advaceutics regime reflect the holistic approach we take from the very beginning, encompassing vital aspects such as safety, stability and cost-effective manufacturing, helping to ensure that the process can be transferred smoothly to large-scale GMP manufacturing at a later stage.
Advaceutics is therefore the overall modus operandi for safeguarding client projects. In short, it comprises the following steps:
– defining the optimal pharmaceutical strategy for a perfect drug presentation through comprehensive consulting
–  applying innovative, science-based technologies to stabilise the native 3D structure of proteins most effectively and reliably throughout the entire shelf life
– developing innovative depot formulations and drug delivery systems for optimised pharmaceutical action
–  identifying the ideal packaging system and delivery device for the drug formulation considering convenience, safety and stability aspects
–  developing reliable and cost-effective manufacturing processes for a pharmaceutical system
–  selecting and qualifying the most suit­able CMO for the pharmaceutical system and transferring the technology into large-scale GMP manufacturing
The Advaceutics process ensures that pharmaceutical clients receive the best solution at the best possible time (with reliable, pre-defined time lines) and a strict management of process risks. Although ProJect Pharmaceutics does not develop pioneering drugs on its own, our team believes it is just as rewarding to actively ensure our clients’ future market success by preparing drugs for market.D


Contact
ProJect Pharmaceutics GmbH
Fraunhoferstrasse 22
82152 Martinsried, Germany
www.project-pharmacutics.com
info@project-pharmaceutics.com
Meet us at CPhI -> Hall 4.1, Booth 41D42

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/from-development-to-launch.html

Events

All Events

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.90 CHF100.3%
  • ADDEX (CH)4.06 CHF84.5%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-28.3%
  • PROSENSA (NL)9.24 USD-28.0%

TOP

  • SANTHERA (CH)68.90 CHF3507.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP771.6%
  • PAION (D)2.80 EUR305.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.24 USD-69.0%

No liability assumed, Date: 24.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products